Novo Nordisk Showcases CagriSema Trial Gains and Wegovy Food Noise Reductions Ahead of FDA Decision
Vandana Singh 7 hours ago
BiotechHealth CareLarge Cap
Novo Nordisk unveils Phase 3 CagriSema weight-loss data and real-world Wegovy food-noise reductions at ObesityWeek 2026 in Washington, D.C.
Novo Nordisk (NYSE:NVO) presented trial and real-world data at ObesityWeek 2026 showing strong weight loss for investigational CagriSema and reduced food noise among Wegovy users.
Read Also: Novo Nordisk Scores EU Win For Hemophilia Drug, Advances Sickle Cell Treatment Toward Approval
CagriSema Delivers Weight Loss Across Lower Doses
On Saturday, Novo Nordisk unveiled primary Phase 3 REDEFINE 9 results in Washington, D.C., alongside simultaneous publication in The Lancet Diabetes & Endocrinology.
The trial tested CagriSema, a fixed-dose combination of cagrilintide and semaglutide, at doses below its 2.4 mg / 2.4 mg maximum.
Assuming full adherence, adults taking the 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg doses achieved 20.7% and 21.0% average weight loss at week 68, versus 2.0% for placebo. They also cut waist circumference by 17.2 cm and 17.5 cm, respectively, compared with 3.6 cm for placebo.
Under the treatment regimen estimand, those doses produced 19.4% and 18.6% weight loss versus 4.6% for placebo.
Early Responders and Quality-of-Life Gains
On Sunday, the company shared two post hoc analyses from the Phase 3 REDEFINE 1 trial of CagriSema 2.4 mg / 2.4 mg. About 67.8% of treated participants lost at least 5% of their body weight by week 8 and reached 25.4% mean weight loss at week 68, versus 17.8% for delayed responders.
At week 68, 73.1% reported meaningful physical function gains and 69.0% reported psychosocial improvements, topping placebo rates of 49.1% and 42.1%.
Novo Nordisk filed a New Drug Application with the U.S. Food and Drug Administration in December 2025 for CagriSema 2.4 mg / 2.4 mg and expects a decision in the fourth quarter of 2026.
U.S. regulators have not approved CagriSema, and trials have not established its safety and efficacy.
Wegovy Reduces Food Noise in Real-World Studies
Novo Nordisk also presented Saturday findings from the retrospective SIGNAL and OCTANE studies using de-identified Ro telehealth data and a seven-item questionnaire tracking intrusive food thoughts.
In SIGNAL, 26,213 adults initiating semaglutide injections cut food-noise scores from a 2.72 baseline by 0.42 points at one month and 0.72 points at six months.
In OCTANE, adults starting oral semaglutide lowered food-noise scores by roughly 25% over three months, while 86.4% reported at least one improvement, including better-fitting clothing (67.5%) and healthier eating (51.6%).
NVO Price Action: Novo Nordisk shares were up 0.73% at $41.94 at the time of publication Monday, according to Benzinga Pro data.
Photo: Shutterstock
